Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients

This is a randomized, double-blinded, placebo-controlled, multi-center phase Ⅲ bridging clinical study designed to evaluate the efficacy, safety, and pharmacokinetic and pharmacodynamic profiles of Motixafortide (BL-8040) + G-CSF vs placebo + G-CSF mobilized hematopoietic stem cells for autologous transplantation in Chinese patients with multiple myeloma.

Participants needed: 60
Trial details
Phase: Phase 3Age: 18-78Biological sex: AllType: InterventionalSponsor: Guangzhou Gloria Biosciences Co., Ltd.Updated: Dec 16, 2025Locations: 2
Eligibility criteria

(Limit: 15,000 characters) [+9]

Previous history of autologous or allogeneic-HCT. [+36]

Status: Recruiting

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

This is a phase I/II study to investigate the safety, tolerability, and preliminary efficacy of GLS-012 monotherapy and in combination with GLS-010 in subjects with advanced solid rumor after progression on standard treatment.

Participants needed: 107
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Guangzhou Gloria Biosciences Co., Ltd.Updated: Jun 18, 2023Locations: 1
Eligibility criteria

Patients who are willing to sign the informed consent form; [+8]

Patients with irAEs of grade ≥ 3 in the previous immunotherapy, and the AEs of t... [+10]

Status: Not yet recruiting

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

This is a randomized, double-blind, placebo-controlled phase III study to evaluate GLS-010 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer.

Participants needed: 424
Trial details
Phase: Phase 3Age: 18-75Biological sex: FemaleType: InterventionalSponsor: Guangzhou Gloria Biosciences Co., Ltd.Updated: Apr 5, 2023Locations: 1
Eligibility criteria

Signed the informed consent form. [+8]

Patients with the opportunity to be cured by surgery and radiotherapy. [+14]